Literature DB >> 28338910

The "Dry-Run" Analysis: A Method for Evaluating Risk Scores for Confounding Control.

Richard Wyss, Ben B Hansen, Alan R Ellis, Joshua J Gagne, Rishi J Desai, Robert J Glynn, Til Stürmer.   

Abstract

A propensity score (PS) model's ability to control confounding can be assessed by evaluating covariate balance across exposure groups after PS adjustment. The optimal strategy for evaluating a disease risk score (DRS) model's ability to control confounding is less clear. DRS models cannot be evaluated through balance checks within the full population, and they are usually assessed through prediction diagnostics and goodness-of-fit tests. A proposed alternative is the "dry-run" analysis, which divides the unexposed population into "pseudo-exposed" and "pseudo-unexposed" groups so that differences on observed covariates resemble differences between the actual exposed and unexposed populations. With no exposure effect separating the pseudo-exposed and pseudo-unexposed groups, a DRS model is evaluated by its ability to retrieve an unconfounded null estimate after adjustment in this pseudo-population. We used simulations and an empirical example to compare traditional DRS performance metrics with the dry-run validation. In simulations, the dry run often improved assessment of confounding control, compared with the C statistic and goodness-of-fit tests. In the empirical example, PS and DRS matching gave similar results and showed good performance in terms of covariate balance (PS matching) and controlling confounding in the dry-run analysis (DRS matching). The dry-run analysis may prove useful in evaluating confounding control through DRS models.
© The Author 2017. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Keywords:  causal inference; disease risk score; epidemiologic methods; prognostic score; propensity score

Mesh:

Year:  2017        PMID: 28338910      PMCID: PMC5411679          DOI: 10.1093/aje/kwx032

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  31 in total

1.  Data, design, and background knowledge in etiologic inference.

Authors:  J M Robins
Journal:  Epidemiology       Date:  2001-05       Impact factor: 4.822

2.  Invited commentary: positivity in practice.

Authors:  Daniel Westreich; Stephen R Cole
Journal:  Am J Epidemiol       Date:  2010-02-05       Impact factor: 4.897

3.  A new weighted balance measure helped to select the variables to be included in a propensity score model.

Authors:  Emmanuel Caruana; Sylvie Chevret; Matthieu Resche-Rigon; Romain Pirracchio
Journal:  J Clin Epidemiol       Date:  2015-05-01       Impact factor: 6.437

4.  Measuring balance and model selection in propensity score methods.

Authors:  Svetlana V Belitser; Edwin P Martens; Wiebe R Pestman; Rolf H H Groenwold; Anthonius de Boer; Olaf H Klungel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-07-29       Impact factor: 2.890

5.  Propensity score balance measures in pharmacoepidemiology: a simulation study.

Authors:  M Sanni Ali; Rolf H H Groenwold; Wiebe R Pestman; Svetlana V Belitser; Kit C B Roes; Arno W Hoes; Anthonius de Boer; Olaf H Klungel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-01-29       Impact factor: 2.890

6.  Reducing Bias Amplification in the Presence of Unmeasured Confounding Through Out-of-Sample Estimation Strategies for the Disease Risk Score.

Authors:  Richard Wyss; Mark Lunt; M Alan Brookhart; Robert J Glynn; Til Stürmer
Journal:  J Causal Inference       Date:  2014-09-01

7.  Using internally developed risk models to assess heterogeneity in treatment effects in clinical trials.

Authors:  James F Burke; Rodney A Hayward; Jason P Nelson; David M Kent
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2014-01-14

8.  Confounder summary scores when comparing the effects of multiple drug exposures.

Authors:  Suzanne M Cadarette; Joshua J Gagne; Daniel H Solomon; Jeffrey N Katz; Til Stürmer
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-01       Impact factor: 2.890

9.  Evaluating medication effects outside of clinical trials: new-user designs.

Authors:  Wayne A Ray
Journal:  Am J Epidemiol       Date:  2003-11-01       Impact factor: 4.897

10.  Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research.

Authors:  Elizabeth A Stuart; Brian K Lee; Finbarr P Leacy
Journal:  J Clin Epidemiol       Date:  2013-08       Impact factor: 6.437

View more
  9 in total

1.  Evaluating Community-Based Translational Interventions Using Historical Controls: Propensity Score vs. Disease Risk Score Approach.

Authors:  Luohua Jiang; Shuai Chen; Janette Beals; Juned Siddique; Richard F Hamman; Ann Bullock; Spero M Manson
Journal:  Prev Sci       Date:  2019-05

2.  Standardizing Discrete-Time Hazard Ratios With a Disease Risk Score.

Authors:  David B Richardson; Alexander P Keil; Jessie K Edwards; Alan C Kinlaw; Stephen R Cole
Journal:  Am J Epidemiol       Date:  2020-10-01       Impact factor: 4.897

3.  A likely responder approach for the analysis of randomized controlled trials.

Authors:  Eugene Laska; Carole Siegel; Ziqiang Lin
Journal:  Contemp Clin Trials       Date:  2022-01-24       Impact factor: 2.226

4.  Synthetic Negative Controls: Using Simulation to Screen Large-scale Propensity Score Analyses.

Authors:  Richard Wyss; Sebastian Schneeweiss; Kueiyu Joshua Lin; David P Miller; Linda Kalilani; Jessica M Franklin
Journal:  Epidemiology       Date:  2022-04-12       Impact factor: 4.860

5.  The use of prognostic scores for causal inference with general treatment regimes.

Authors:  Tri-Long Nguyen; Thomas P A Debray
Journal:  Stat Med       Date:  2019-01-16       Impact factor: 2.373

6.  Controlling Confounding in a Study of Oral Anticoagulants: Comparing Disease Risk Scores Developed Using Different Follow-Up Approaches.

Authors:  Justin Bohn; Sebastian Schneeweiss; Robert J Glynn; Sengwee Toh; Richard Wyss; Rishi Desai; Joshua J Gagne
Journal:  EGEMS (Wash DC)       Date:  2019-07-15

7.  On the aggregation of published prognostic scores for causal inference in observational studies.

Authors:  Tri-Long Nguyen; Gary S Collins; Fabio Pellegrini; Karel G M Moons; Thomas P A Debray
Journal:  Stat Med       Date:  2020-02-05       Impact factor: 2.373

8.  Use of clinical pharmacy services by American Indians and Alaska Native adults with cardiovascular disease.

Authors:  Joan O'Connell; Laura Grau; Spero M Manson; Anne Marie Bott; Kyle Sheffer; Randy Steers; Luohua Jiang
Journal:  J Am Coll Clin Pharm       Date:  2022-05-25

9.  Using Real-World Data to Predict Clinical and Economic Benefits of a Future Drug Based on its Target Product Profile.

Authors:  Christoph Gerlinger; Thomas Evers; Jeremy Rassen; Richard Wyss
Journal:  Drugs Real World Outcomes       Date:  2020-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.